Powered by

Longtime Gilead captain John Martin, mastermind of lifesaving HIV, hep C drugs, has died

Mar 31, 2021 - FiercePharma
Board and Executive Moves

John Martin, the CEO who shaped Gilead Sciences into the antiviral giant that it is today, has passed away. He was credited with turning Gilead into a biopharma powerhouse with a $100 billion market cap and multibillion-dollar revenues from practice-changing antivirals for HIV and hepatitis C.

John Martin, Ph.D., the CEO who shaped Gilead Sciences into the antiviral giant that it is today, has passed away.

Gilead announced Martin's death early Wednesday. He was the California drugmak...